Tat-BECN1 increases the release of insulin in murine and human primary islets (Goginashvili et al., 2015) (Tat-BECN1 is also reported to reduce adenosine-stimulated insulin secretion in islets (Israeli et al., 2018)), the secretion of candidate protein biomarkers of tumor cell autophagy (Kraya et al., 2015), and the production of monoclonal antibody in CHO cells (Braasch et al., 2021). This evidence concerns the gene BECN1 and neoplasm.